CompletedNot Applicable

The Effect of Preoperative Mirabegron Use on Ureteral Access Sheath Insertion

Turkey (Türkiye)125 participantsStarted 2022-01-01

Plain-language summary

The aim of this study is to evaluate whether there is a difference in the passage rate of the ureteral access sheath between patients who used mirabegron (a beta-3 receptor agonist) for overactive bladder and those who underwent retrograde intrarenal surgery for kidney stones, and those who did not use mirabegron. Considering that beta-3 receptors in the smooth muscle of the ureter cause relaxation in the ureter, the hypothesis that the passage rate of the access sheath increases in those using mirabegron, thus facilitating access to kidney stones and improving surgical success, will be investigated.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patients scheduled for RIRS due to kidney stones Exclusion Criteria: * preoperative ureteral stenting, * ureteral strictures, history of ureteral or bladder surgery, * anatomical abnormalities of the urinary tract, * active urinary tract infection, * pregnancy, * uncontrolled hypertension (systolic blood pressure ≥180 mmHg, diastolic blood pressure ≥110 mmHg), * use of medications affecting ureteral smooth muscle tone

What they're measuring

Ureteral access sheath insertion rate

Timeframe: From January 2022 to December 2024

Trial details

NCT IDNCT07566416

SponsorAnkara Training and Research Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-12-12

View on ClinicalTrials.gov More Kidney Stone trials